ImmunoPrecise Antibodies Ltd. Files 6-K Report
Ticker: HYFT · Form: 6-K · Filed: Oct 2, 2024 · CIK: 1715925
Sentiment: neutral
Topics: filing, press-release, regulatory-update
TL;DR
IPA files 6-K with press release, check 20-F for annual reports.
AI Summary
ImmunoPrecise Antibodies Ltd. filed a Form 6-K on October 2, 2024, to report a press release dated October 2, 2024. The filing indicates the company is a foreign private issuer and will file annual reports under Form 20-F. The principal executive office is located in Victoria, British Columbia.
Why It Matters
This filing serves as an update for investors regarding the company's reporting status and includes a press release, which may contain important business developments.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) that primarily serves to attach a press release and confirm reporting status, with no immediate financial or operational disclosures that would suggest high risk.
Key Players & Entities
- ImmunoPrecise Antibodies Ltd. (company) — Filer of the report
- October 2, 2024 (date) — Date of the press release and filing
- Kristin Taylor (person) — Signatory for the company
- 001-39530 (other) — Commission File Number
FAQ
What is the purpose of this Form 6-K filing?
The Form 6-K is being filed to report a press release dated October 2, 2024, and to indicate that ImmunoPrecise Antibodies Ltd. files annual reports under Form 20-F.
What is the filing date of this report?
The filing date is October 2, 2024.
Where is ImmunoPrecise Antibodies Ltd.'s principal executive office located?
The principal executive office is located at 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8.
What exhibit is included with this Form 6-K?
Exhibit 99.1, a Press Release dated October 2, 2024, is included with this Form 6-K.
Who signed this report on behalf of ImmunoPrecise Antibodies Ltd.?
The report was signed by Kristin Taylor, who is duly authorized.
Filing Stats: 143 words · 1 min read · ~1 pages · Grade level 11.2 · Accepted 2024-10-02 08:02:26
Filing Documents
- press_release_oct_2_2024.htm (6-K) — 21KB
- ipa-ex99_1.htm (EX-99.1) — 19KB
- 0000950170-24-111108.txt ( ) — 41KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. IMMUNOPRECISE ANTIBODIES LTD. Date: October 2, 2024 By: /s/ Kristin Taylor Name: Kristin Taylor Title: Chief Financial Officer